News from the 3D Lab- this time tablets are on

Quantum leap innovation from the perspective of research institutes


How do employees of research institutes assess this assessment of the quantum leap potential of the 3D tablet?


It seems that so far, especially English pharmaceutical research institutes have been dealing with the topic of 3D printing of tablets, at least if one judges by the corresponding publications. Since the methodology of 3D printing of tablets is not yet fully developed (see also the already published blog: 3D Technology for Tablets-the gentle disruption; Quantum Leap Innovation from the perspective of technology providers), there are still interesting research areas for galenics. In addition to previously unusual forms for 3D tablets (e.g. ring structures with a large surface area for optimized release of active ingredients), active ingredient combinations in multi-layer cylindrical ring-shaped products are also being produced. For example, combinations of analgesics, hydrochlorothiazides, atenolol, pravastatin and ramipril are selected. The extent to which such a combination of active substances is clinically useful, however, will not be described. In fact, there is an almost complete lack of clinical studies that could validate the use of such 3D tablets from research.


Thus, the research institutes are more responsible for optimizing the galenic and methodological processes for 3D printing of tablets and not necessarily for determining the next steps for implementation (e.g. GMP-compliant 3D printing processes).


How do employees of academic research institutes rate this assessment of the quantum leap potential of 3D tablets?


Note: the entire article represents the opinion of the author and not that of one of his previous or current employers and this publication is not supported by them in any way.


Interested in more blogs about 3D printing?


In the previous episode, a quantum leap innovation was explained from the perspective of start-ups.


In the next episode, the quantum leap innovation is explained from the perspective of legal experts and patent attorneys.


Dr. Volker Moeckel

Kommentar schreiben

Kommentare: 0